Clinical outcomes, predictors of prognosis and health economics consequences in IBD patients after discontinuation of the first biological therapy.

Journal: Therapeutic advances in gastroenterology
Published Date: Dec 27, 2020

Abstract

BACKGROUND: In real-world clinical practice, biologics in inflammatory bowel diseases (IBD) may be discontinued for a variety of reasons, including discontinuation initiated by gastroenterologists. The aims of the study are to report outcomes after discontinuation and predictors of prognosis after a minimum follow-up of 24 months; outcomes of gastroenterologist-initiated discontinuation with resulting direct cost implications on the health system were also studied.

Authors

  • Uday N Shivaji
    National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, Birmingham, UK.
  • Alina Bazarova
    Institute of Translational Medicine, Birmingham, UK.
  • Tamsin Critchlow
    University Hospitals Birmingham, Birmingham, UK.
  • Samuel C L Smith
    Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Olga Maria Nardone
    Institute of Immunology and Immunotherapy, University of Birmingham, UK.
  • Melanie Love
    University Hospitals Birmingham, Birmingham, UK.
  • Joanne Davis
    University Hospitals Birmingham, Birmingham, UK.
  • Subrata Ghosh
    Professor of Medicine and Gastroenterology, Director, Institute of Translational Medicine, University of Birmingham, Edgbaston, Birmingham, B15 2TH, UK.
  • Marietta Iacucci
    National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, Birmingham, UK.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals